Abemaciclib (ABE), ribociclib (RIB), and palbociclib (PAL) are CDK4/6 inhibitors that work by targeting overactive CDK4/6 in cancer cells and stopping their cell cycle, thereby slowing proliferation [6]. Here, CDK4 is linked to cancer.